U n c o r r e c t e d A u t h o r P r o o f Kidney Cancer xx (20xx) x-xx Abstract. 28 Background: We investigated outcomes with cabozantinib versus everolimus in patients with advanced renal cell carcinoma (RCC) with or without prior nephrectomy in the phase 3 METEOR trial (NCT01865747).
INTRODUCTION 31
The clinical benefit of nephrectomy in patients 32 with metastatic renal cell carcinoma (RCC) was 33 initially reported in 2001 [1] [2] [3] . In phase 3 trials, 34 patients who underwent nephrectomy followed by 35 interferon-␣ had improved overall survival (OS) com-36 pared with patients treated with interferon-␣ therapy 37 alone. The underlying biology of this benefit was not 38 fully understood; but in addition to tumor debulking, 39 data indicated that nephrectomy reduced immuno-40 suppressive cytokines and tumor-promoting growth 41 factors [4] [5] [6] . Nephrectomy with cytokine therapy 
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